ACSF3基因变异所致丙二酸联合甲基丙二酸尿症患儿临床特征分析
该病例系列研究纳入7例ACSF3基因变异所致CMAMMA患儿,男6例、女1例,发病年龄1.0(0.4,8.0)岁,6例未出现急性代谢危象。主要生化特征为尿甲基丙二酸均升高、5例伴尿丙二酸升高,血酰基肉碱谱多正常;5例对维生素B12治疗无效,随访5例发育迟缓或边缘状态、1例发育正常、1例死亡。结论为该病临床表型高度异质性,部分预后不良。
要点
- 尿甲基丙二酸升高为主,伴或不伴尿丙二酸升高,血酰基肉碱谱常正常。
- 7例中5例维生素B12无效,血丙酰肉碱及同型半胱氨酸均正常。
- 基因检测发现11种ACSF3变异,含2种未报道变异。
核心结论
- ACSF3基因变异所致CMAMMA临床表型高度异质性,部分患儿预后不良。
研究设计与样本
- 病例系列研究,纳入2021年12月至2025年11月在上海交通大学医学院附属新华医院儿内分泌遗传代谢科就诊的7例CMAMMA患儿,男6例、女1例。
主要发现
- 7例患儿发病年龄为1.0(0.4,8.0)岁,6例未出现急性代谢危象。
- 5例存在不同程度智力发育迟缓,其中1例合并癫痫发作、1例合并肌张力低下。
- 7例尿甲基丙二酸均高于正常值,5例伴尿丙二酸高于正常值,血丙酰肉碱和同型半胱氨酸均正常,仅1例丙酰肉碱/乙酰肉碱轻度升高。
- 5例为维生素B12无效型;基因检测发现ACSF3基因11种变异,其中c.785C>T(p.A262V)和c.889T>A(p.Y297N)为未报道变异。
- 随访5例处于重度发育迟缓或边缘状态,1例发育正常,1例死亡。
临床怎么用
- 对疑似CMAMMA患儿应结合尿有机酸分析(甲基丙二酸及丙二酸)与ACSF3基因测序明确诊断。
- 血酰基肉碱谱正常不能排除CMAMMA,需重视尿甲基丙二酸检测。
- 评估维生素B12反应性有助于分型,并需长期随访发育情况与预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical characteristics, genetic variants and outcomes of children with combined malonic and methylmalonic aciduria (CMAMMA) caused by ACSF3 gene variant. Methods: This was a retrospective case series. Clinical manifestations, biochemical findings, genetic sequencing and outcomes were collected from 7 infants with CMAMMA who were evaluated at the Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine between December 2021 and November 2025. Blood acylcarnitine profiles were analyzed by tandem mass spectrometry, urinary organic acids by gas chromatography-mass spectrometry and causative variants by Sanger or next generation sequencing. Results: The cohort included 6 males and 1 female, with an age at onset of 1.0 (0.4, 8.0) years and 6 patients did not experienced acute metabolic decompensation during the neonatal or infantile period. Five patients had varying degrees of developmental delay, including 1 patient with seizures and 1 patient with hypotonia. Biochemical analysis revealed elevated urinary methylmalonic acid level in all patients, and 5 patients also had elevated urinary malonic acid levels. Plasma propionylcarnitine (C3) and homocysteine levels were within normal ranges in all patients, while a mildly increased C3/acetylcarnitine (C2) ratio was observed in 1 patient. Five patients were unresponsive to vitamin B12 therapy. Genetic analysis identified 11 ACSF3 gene variants, including 2 novel variants, c.785C>T (p.A262V) and c.889T>A (p.Y297N). Follow-up assessments showed 5 patients exhibited severe or borderline developmental delay, 1 patient developed normally and 1 patient died. Conclusions: CMAMMA caused by ACSF3 variants is characterized by marked phenotypic heterogeneity and a subset of patients experience unfavorable outcomes. The predominant biochemical finding is elevated urinary methylmalonic acid, with or without concurrent elevation of malonic acid, while blood acylcarnitine profiles were often within the normal range. 目的: 探讨ACSF3基因变异所致丙二酸联合甲基丙二酸尿症(CMAMMA)患儿的临床特征、基因变异特点及预后。 方法: 病例系列研究。收集2021年12月至2025年11月在上海交通大学医学院附属新华医院儿内分泌遗传代谢科就诊的7例CMAMMA 患儿的临床表现、实验室检查、基因测序结果及转归等临床资料。采用串联质谱法检测血酰基肉碱水平,气相色谱-质谱法检测尿有机酸分析,Sanger或二代测序检测致病基因。 结果: 7例患儿中男6例、女1例,发病年龄为1.0(0.4,8.0)岁,6例未出现急性代谢危象。临床表现为5例患儿存在不同程度智力发育迟缓,其中1例合并癫痫发作、1例合并肌张力低下。7例患儿尿甲基丙二酸水平均高于正常值,其中5例伴尿丙二酸水平高于正常值,血丙酰肉碱、同型半胱氨酸均正常,仅1例丙酰肉碱/乙酰肉碱轻度升高。5例患儿为维生素B12无效型。基因检测发现ACSF基因11种变异,其中c.785C>T(p.A262V)和c.889T>A(p.Y297N)为未报道变异。5例患儿发育情况处于重度发育迟缓或边缘状态,1例发育正常,1例死亡。 结论: CMAMMA患儿临床表型高度异质性,部分预后不良。生化特征以尿甲基丙二酸升高为主,伴或不伴尿丙二酸升高,血酰基肉碱谱多正常。.
引用
- Ding Y, Deng YX, Hao LL, et al. [Analysis of clinical characteristics of children with combined malonic and methylmalonic aciduria]. Zhonghua Er Ke Za Zhi. 2026. PMID: 42135235. doi:10.3760/cma.j.cn112140-20260204-00114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。